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Systemic and glomerular hypertension and progression of
chronic renal disease: The dilemma of nephrosclerosis. The
link between the kidney and hypertension has been consid-
ered a villain-victim relationship. High blood pressure levels
are a well-recognized feature in chronic renal disease, but
the ability of mild-to-moderate hypertension to produce re-
nal insufficiency has been questioned. Nephrosclerosis, benign
nephrosclerosis, and hypertensive kidney disease are terms that
clinicians use when renal damage is thought to be secondary
to essential hypertension. Many cases of end-stage renal dis-
ease are ascribed to so-called benign nephrosclerosis. This en-
tity could actually be a primary renal disease affecting the
preglomerular microvasculature, perhaps genetically mediated
and ethnically influenced, and showing a heterogeneous clin-
ical expression. African Americans suffer from nephrosclero-
sis more frequently than Caucasians. Nephrosclerosis affecting
Caucasians seems to show a less aggressive pattern and could
represent early age-related renal sclerosis. The risk of end-stage
renal disease is increased when atherosclerotic lesions in large
renal arteries coexist. Age, systolic blood pressure, protein-
uria, and concomitant cardiovascular disease are well-known
promoters of renal failure. A multifactorial strategy, including
antihypertensive and antiproteinuric drugs, and lipid-lowering
and anti-platelet agents, could improve cardiovascular and re-
nal outcomes in patients with nephrosclerosis.
The link between the kidney and hypertension has
been considered a villain-victim relationship because of
the potential two-way causality between high blood pres-
sure (BP) and renal disease. Guyton et al stated more than
30 years ago that the kidneys play a key role in the con-
trol of sodium homeostasis and through this mechanism
on blood pressure regulation [1]. Primary renal diseases
cause secondary hypertension, and malignant hyperten-
sion has been associated with the development of renal
dysfunction. Furthermore, high BP is a marker of estab-
lished renal disease, and strict BP control has been consid-
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ered the basis of therapy for slowing renal deterioration
[2–4]. Nevertheless, the risk of renal failure due to less
severe hypertension has been a matter of debate [5].
Nephrosclerosis, benign nephrosclerosis, hypertensive
kidney disease, or nephroangiosclerosis are terms that
clinicians use to identify renal damage associated with
essential hypertension. Two clinicopathologic patterns
have been described. One is malignant nephrosclerosis,
which is associated with accelerated or malignant hy-
pertension and characterized by fibrinoid necrosis and
myointimal hyperplasia. If left untreated, progressive re-
nal insufficiency occurs. Malignant nephrosclerosis is a
rare entity today because of improvements in antihy-
pertensive management [6]. The other form is the so-
called benign nephrosclerosis or simply nephrosclerosis,
in which histopathologic features include microvascular
changes with hyalinosis of the preglomerular vessel walls
and thickening of the intima and reduplication of the
internal elastic lamina of the arcuate and interlobar ar-
teries. These changes may lead to glomerular damage,
glomerulosclerosis, patchy tubular atrophy, and intersti-
tial fibrosis. Nephrosclerosis has actually been seen as a
form of intrarrenal renovascular disease [7, 8]. Neverthe-
less, a specific linkage between mild-to-moderate essen-
tial hypertension and nephrosclerosis has been debatable,
because these histologic abnormalities have also been de-
scribed in the aging process, in diabetic nephropathy, and
in advanced stages of various nephropathies [9–11]. Fur-
thermore, the diagnosis of hypertensive nephrosclerosis
is usually presumptive because few patients with essen-
tial hypertension undergo renal biopsy, which leads to a
lack of accuracy if strict clinical diagnostic criteria are not
fulfilled [5, 12].
Although these controversies exist, in the past two
decades nephrosclerosis has been recognized as a pro-
gressively increasing cause of end-stage renal disease
(ESRD). Registries from the United States and Europe
indicate that diabetic nephropathy and nephrosclerosis
are the leading causes of ESRD.
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Table 1. Studies analyzing the incidence of renal disease in relation to blood pressure
Study Patients/Subjects N Main results
Shulman et al, 1989 [13] Participants in the HDFP study 10,940 Baseline BP predicted increase in serum creatinine
Perneger et al, 1993 [14] General population 1399 Baseline BP predicted serum creatinine 12 years
later
Perry et al, 1995 [15] Hypertensive patients of the VA 11,912 Baseline BP predicted ESRD 15 years later
Klag et al, 1996 [16] Participants in the MRFIT study 332,544 Continuous relation between BP and risk of ESRD
16 years later
Siewert-Delle et al, 1998 [17] Participants in the Go¨teborg study 686 Treated patients with hypertension did not develop
ESRD after 20 years of follow-up
Young et al, 2002 [18] Participants in the SHEP study 2181 Systolic BP was an independent predictor for
kidney function decline
Tozawa et al, 2003 [19] Participants in the Okinawa study 98,759 Continuous relationship between BP and risk of
ESRD 17 years later
Vupputuri et al, 2003 [20] Treated male patients with hypertension 722 Uncontrolled BP predicted early renal function
decline
Segura et al, 2004 [21] Treated patients with hypertension 281 14.6% developed renal disease in a 13-year
follow-up
Hsu et al, 2005 [22] General population with baseline
normal renal function
316,675 Continuous relationship between BP and remote
risk of ESRD
Abbreviations are: HDFP, Hypertension Detection and Follow-up Program; BP, blood pressure; VA, Veterans Administration Hypertension Screening and Treatment
Program; ESRD, end-stage renal disease; MRFIT, Multiple Risk Factor Intervention Trial; SHEP, Systolic Hypertension in the Elderly Program.
DOES MILD-TO-MODERATE ESSENTIAL
HYPERTENSION LEAD TO RENAL FAILURE?
The risk of ESRD associated with nonmalignant hy-
pertension has been investigated only recently. The ma-
jority of studies assessing this issue have been short-term
evaluations of small sample size and post hoc analyses of
epidemiologic observations. Although these studies have
been criticized because of various limitations, an increas-
ing amount of evidence links mild-to-moderate essential
hypertension with the development of ESRD (Table 1)
[13–22]. Three large cohort studies have reported that
elevated BP predicts remote risk of renal failure. Klag
et al [16] analyzed data from 332,544 men who were
screened for the Multiple Risk Factor Intervention Trial,
and Tozawa et al [19] evaluated data from 98,759 men
and women who were screened in Okinawa, Japan. Both
studies showed an increasing relationship between base-
line BP, from the high-normal stage, and the risk of ESRD
16 to 17 years later. Because renal function was not care-
fully evaluated at baseline in the Multiple Risk Factor
Intervention Trial and Okinawa studies, it is conceivable
that renal disease was already present in those patients
who later developed ESRD. Nevertheless, Hsu et al [22]
have recently published a similar analysis of 316,675 indi-
viduals with baseline-estimated glomerular filtration rate
≥60 mL/min/1.73 m2 and negative proteinuria or hema-
turia by dipstick urinalysis. They observed that even rel-
atively modest elevations in BP from optimal levels were
independently related to the incidence of ESRD.
DOES TREATED MILD-TO-MODERATE
ESSENTIAL HYPERTENSION CAUSE RENAL
FAILURE?
Few studies have evaluated the incidence of renal fail-



















Fig. 1. Essential hypertension and ESRD. When essential hyperten-
sion is associated with ESRD, many other conditions (right side) could
be present. Reproduced from Ljungman [25], with permission.
[17, 23, 24]. Siewert-Delle et al [17] analyzed the develop-
ment of renal disease in 686 white men with treated hyper-
tension during a 20-year follow-up. Incidence of a serum
creatinine level above 1.5 mg/dL was observed in 8.9% of
patients, but an underlying renal abnormality was found
in the majority of such cases. Only 1.7% of the whole sam-
ple showed an unexplained increase in serum creatinine,
but none of these cases developed ESRD. The authors
concluded that controlled nonmalignant essential hyper-
tension did not lead to ESRD or clinically significant renal
dysfunction. It has been stated that a myriad of other con-
ditions could actually be the cause of ESRD attributed to
essential hypertension in Caucasians (Fig. 1) [25]. Never-
theless, in African American patients, who show a special
susceptibility to nephrosclerosis, it has been documented
progression to ESRD [26].
S-54 Marı´n et al: The dilemma of nephrosclerosis
A meta-analysis including data from classical random-
ized clinical trials of antihypertensive therapy that eval-
uated renal dysfunction among the outcomes has been
published. There was no difference in the relative risk
of developing renal dysfunction between actively treated
cases and control patients [27]. It can be argued that non-
malignant hypertension is not a cause of ESRD, because
no beneficial effect of correcting high BP was observed
as compared with leaving hypertension untreated.
Some authors suggest that nephrosclerosis is actually
an intrinsic dysfunction of the preglomerular microvas-
culature primarily causing afferent arteriole vasocon-
striction. This abnormality could lead to high BP and
glomerular injury, and subsequently renal scarring [7].
Renal function deterioration would be slow and almost
indistinguishable from that related with normal aging,
but some circumstances such as atherosclerotic renal
artery disease or diabetes could precipitate renal failure.
Nephrosclerosis could be the renal expression of a sys-
temic disorder causing other vascular alterations such as
coronary heart disease or cerebrovascular disease. Tracy
et al [28] showed, in an autopsy study of patients aged
25 to 54 years with deaths unrelated to atherosclerosis,
that there was an association between incipient intrarenal
vascular damage and coronary artery or aorta diseases.
Keller et al [29] have recently reported that the number
of glomeruli was lower in the kidneys of hypertensive pa-
tients when comparing with that of controls with normal
BP. Individuals with a nephron number at the lowest per-




As stated before, the diagnosis of nephrosclerosis is
usually a presumption because histopathologic confirma-
tion is often lacking. Findings should suggest nephroscle-
rosis as the cause of renal dysfunction when the patient
has long-standing hypertension, is of male sex, is aged
>55 years, has a family history of hypertension, has signs
of hypertensive damage in other territories such as left
ventricular hypertrophy or retinopathy, extrarenal mani-
festations of atherosclerosis, relatively slow deterioration
of renal function, and has no data pointing to another pri-
mary nephropathy such as significant proteinuria and/or
hematuria. However, the clinical diagnosis of nephroscle-
rosis can be inaccurate despite fulfilling these criteria as
shown by Zucchelli and Zuccala` [30] in 56 patients dia-
gnosed as having nephrosclerosis. When kidney biopsy
or renal angiography was performed, only 46% of pa-
tients retained the original diagnosis. Similarly, Zarif et al
[12] found in a retrospective analysis that the presump-
tive diagnosis of nephrosclerosis was correct in only 50%
of cases. Nevertheless, the primary cause of misdiagnosis
was renovascular disease, which shows the close relation-
ship between the clinical diagnosis of nephrosclerosis, in-
trarenal vascular damage, and large renal artery disease.
PROGNOSIS OF NEPHROSCLEROSIS
Progression of renal insufficiency, secondary to
nephrosclerosis, used to be relatively slow when com-
pared with that of primary glomerulopathies or diabetic
nephropathy [26, 31]. Renal function often remains sta-
ble during prolonged periods of time provided that BP is
adequately controlled, although some patients progress
to ESRD. Factors promoting this ominous prognosis are
not fully identified, although known markers for unfavor-
able renal outcomes are age, African descent, systolic BP
levels, proteinuria, and concomitant cardiovascular dis-
eases. Vikse et al [32] have reported that 32% of patients
with biopsy-proven benign nephrosclerosis developed
ESRD during a 13-year follow-up. Forty-seven percent of
these patients died during the same period. Marcantoni
et al [33] performed a retrospective analysis of biopsies
with a diagnosis of hypertensive nephrosclerosis and de-
scribed two different phenotypes of glomerulosclerosis
related to race. African Americans were younger and
showed higher levels of serum creatinine at the time of
biopsy when compared with Caucasians. Glomeruloscle-
rosis and interstitial fibrosis were more pronounced in
African Americans. Morphologic abnormalities in Cau-
casians mimic those related to aging.
Nephrosclerosis is being increasingly diagnosed in
older patients with cardiovascular diseases. Nephroscle-
rosis in patients older than 65 years could actually
represent an added expression of diffuse atherosclero-
sis. Coexistence of intrarenal microvascular lesions with
atherosclerotic changes in large arteries is a common find-
ing. Nephrosclerosis can thus be seen as a component of
renal vascular disease comprising renal artery disease, is-
chemic nephropathy, or even cholesterol atheroembolic
disease. Other alterations such as diabetes, metabolic syn-
drome, and/or dyslipidemia could act as aggravating con-
ditions. Renal function at diagnosis and histologic status
of renal tissue are key factors in prognosis, because ag-
gressive intervention to correct lesions in large vessels
does not often improve outcomes [34]. Factors influenc-
ing the development of nephrosclerosis are illustrated in
Figure 2.
Some authors have recently reported that concomitant
cardiovascular disease was associated with a poor prog-
nosis [35, 36]. Levin et al [35] showed a 1.58 relative risk
of ESRD in patients with renal insufficiency and cardio-
vascular disease versus patients with renal insufficiency
but free of cardiovascular disease. A decrease in the cir-
culatory status due to cardiovascular events would lead
to deterioration of renal function, which starts a vicious
circle in which the deleterious milieu of chronic kidney


























Fig. 2. Factors influencing in the develop-
ment of nephrosclerosis. Initiators could be
genetic, an intrinsic abnormality of pre-
glomerular microvasculature, and/or a con-
genital reduction in nephron number. In the
elderly, the aging process could be acceler-
ated by concomitant cardiovascular disease
and/or atherosclerotic aortorenal changes.
Other conditions (gray shadowed) could act
as aggravating factors.
Table 2. Integrated approach for renoprotection and cardiovascular
prevention in patients with chronic kidney disease
Goals
BP control <130/80 mm Hg
Many patients will need two or more antihypertensive drugs
Reduction of proteinuria <0.5 g/day or ratio of protein to creatinine
on spot urine collection <200 mg/g
Considered a BP-independent goal
Dual blockade with ACE inhibitors and ARBs may exert an
additional benefit
HbA1c <7% in diabetics
Smoking cessation
Lipid-lowering therapy
Total cholesterol <175 mg/dL and LDL cholesterol <100 mg/dL
Anti-platelet therapy
Control of calcium-phosphorus product <55 mg2/dL2
Control of anemia >12 g/dL
Antihypertensive therapy
First step, ACE inhibitor or ARB
Try to up-titrate to high doses, because the antiproteinuric effect is
probably dose-dependent
Monitor serum creatinine and potassium 1 to 2 weeks after
initiation
Second step, diuretic
In stages 3 and 4, loop diuretic
Third step, calcium-channel blocker or beta-blocker
Beta-blocker preferred if coronary heart disease or heart failure
Fourth step, beta-blocker or calcium-channel blocker if not used
before.
Consider other alternatives such as alpha-blockers or centrally
acting drugs
Abbreviations are: BP, blood pressure; ACE, angiotensin-converting
enzyme; ARB, angiotensin II receptor blocker; HbA1c, hemoglobin A1c; LDL,
low-density lipoprotein.
disease, and the so-called therapeutic nihilism that renal
patients suffer from, accelerates cardiovascular disease.
THERAPEUTIC OPTIONS
There are few studies dealing with treatment for
nephrosclerosis. The African American Study of Kidney
Disease and Hypertension [37] recruited 1094 African
Americans with hypertensive renal disease that were ran-
domly assigned to one of two mean BP goals (102 or
107 mm Hg) and to treatment based on a beta-blocker,
an angiotensin-converting enzyme (ACE) inhibitor, or a
calcium-channel blocker. The outcome was no different
between the two BP groups. Patients receiving the ACE
inhibitor-based therapy showed a 22% reduction in risk of
the composite end point that included unfavorable renal
outcomes and death. Segura et al [38] performed a retro-
spective analysis of Spanish patients diagnosed as hav-
ing nephrosclerosis. Patients receiving ACE inhibitors
showed a marked reduction in the risk of a 50% reduction
in creatinine clearance during a 7-year follow-up.
Renal and cardiovascular risk is highly increased in pa-
tients with nephrosclerosis. A multifactorial therapeutic
approach for chronic kidney disease has been recently
proposed to minimize both renal and cardiovascular
events (Table 2). This strategy might prevent patients
with nephrosclerosis from progressing to ESRD and car-
diovascular disease.
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